伦敦生物技术初创公司Baseimmune近日在A轮融资中成功募集1130万美元（约900万英镑），这笔资金将用于加速其利用人工智能设计和开发疫苗的创新平台。Baseimmune的机器学习技术旨在简化疫苗设计过程，为全球公共卫生领域带来革命性的变化。
本轮融资获得了超额认购，参与的投资者阵容强大，包括MSD Global Health Innovation Fund、IQ Capital等知名投资机构，以及Baseimmune的早期支持者Hoxton Ventures、Creator Fund、Beast Ventures和Maki.vc。这些投资方的加入，不仅体现了市场对Baseimmune技术潜力的认可，也彰显了他们对利用AI技术推动医疗进步的坚定信心。
Baseimmune的这一举措预示着未来疫苗研发可能进入一个全新的时代，通过AI的精准计算和预测能力，有望缩短疫苗研发周期，提高疫苗的安全性和有效性。随着资金的注入，Baseimmune将进一步提升其研发能力，为应对全球性的传染病挑战提供更快速、更有效的解决方案。
英语如下：
**News Title:** “London-based Biotech Company Baseimmune Raises $11.3 Million for AI-Powered Vaccine Design Platform”
**Keywords:** Baseimmune, vaccine development, AI funding
**News Content:** London-based biotech startup Baseimmune has recently secured $11.3 million (approximately £9 million) in its Series A funding round, which will be allocated to accelerate its innovative platform for designing and developing vaccines using artificial intelligence. The company’s machine learning technology aims to streamline the vaccine design process, potentially revolutionizing global public health.
The funding round was oversubscribed, with a notable lineup of investors, including MSD Global Health Innovation Fund and IQ Capital, among others. Early backers Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc also participated. This strong investor interest not only underscores the recognition of Baseimmune’s technological potential but also demonstrates their commitment to advancing healthcare through AI-driven solutions.
Baseimmune’s approach signals a potential new era in vaccine development, where AI’s precision computing and predictive capabilities could shorten development timelines and enhance vaccine safety and efficacy. With the influx of funds, the company is poised to enhance its research capabilities, offering faster and more effective solutions to combat global infectious disease challenges.
【来源】https://www.maginative.com/article/baseimmune-closes-11-3m-series-a-to-accelerate-ai-designed-vaccines/
Views: 1